SEHK:9926Biotechs
Akeso (SEHK:9926) FY 2025 Loss Deepens Despite 2H Revenue Growth Challenging Bullish Narratives
Akeso (SEHK:9926) has reported FY 2025 results with second half revenue of C¥1.6b and a basic EPS loss of C¥0.60, while trailing 12 month revenue reached C¥3.1b against a net loss of C¥1.1b. The business has seen revenue move from C¥1.1b in 2H 2024 to C¥1.6b in 2H 2025, with basic EPS shifting from a loss of C¥0.32 to a loss of C¥0.60 over the same period, as investors weigh growth in the top line against persistent losses. Overall, the latest numbers point to expanding operations but...